Russia has become the first country in the world to register a vaccine against COVID-19, President Vladimir Putin announced on Tuesday August 11, 2020, during a government meeting.
Putin also asked Health Minister Mikhail Murashko to keep him informed about the vaccine, while at the same time noting that he knows “it works quite effectively” and “forms a stable immunity”.
“I hope we will be able to start mass production of this medication in the near future, which is very important”, the president said.
Putin further thanked everyone who worked on the first-ever vaccine against the coronavirus, and described it as “a very important step for the world”.
“I hope that our colleagues abroad will also move forward, and there will be quite a lot of products that can be used on the market, on the world market for medicines and vaccines”, Putin continued.
The Russian president also revealed that one of his daughters had been vaccinated against the coronavirus.
“In this sense, she took part in the experiment. After the first vaccination, she had a body temperature of 38 degrees Celsius, while the following day it was slightly over 37 degrees Celsius, that’s it. After the second injection, the second vaccination, her temperature also rose a little, and then everything cleared up, she feels good and the [antibody] titers are high”, Putin stated.
Meanwhile, Russian Health Minister Mikhail Murashko has said that the first Russian vaccine against the coronavirus will begin to be produced at two sites – the Gamaleya Research Institute and the company Binnopharm.
The minister also announced that a number of countries are already showing interest in the vaccine, and the Russian Direct Investment Fund (RDIF) is investing in the production and promotion of the vaccine abroad.
The vaccine was developed by the Gamaleya Research Institute. It has two separately-injected components that together are expected to build long-term immunity against the virus.
Clinical trials of the vaccine kicked off on 18 June and included 38 volunteers. All of the participants developed an immunity. The first group was discharged on 15 July, the second group on 20 July.
